Maze Therapeutics (NASDAQ:MAZE) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Maze Therapeutics (NASDAQ:MAZE) from a hold rating to a sell rating in a report released on Saturday morning.

MAZE has been the topic of a number of other reports. JPMorgan Chase & Co. raised their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research note on Monday, September 29th. Wedbush increased their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Guggenheim reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Friday, December 19th. BTIG Research upped their price objective on shares of Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Raymond James Financial started coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and an average target price of $44.50.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $40.77 on Friday. The stock’s fifty day moving average price is $38.71 and its two-hundred day moving average price is $26.96. Maze Therapeutics has a one year low of $6.71 and a one year high of $43.29. The firm has a market cap of $1.96 billion and a price-to-earnings ratio of -1.95.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insiders Place Their Bets

In other news, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. This represents a 87.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $39.15, for a total value of $195,750.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $507,579.75. This represents a 27.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 167,500 shares of company stock worth $6,774,667.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. lifted its position in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Maze Therapeutics by 23.0% in the third quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock worth $135,000 after purchasing an additional 977 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Maze Therapeutics by 33.6% in the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after purchasing an additional 1,455 shares in the last quarter. Russell Investments Group Ltd. raised its position in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the 3rd quarter valued at $52,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.